Success Metrics

Clinical Success Rate
92.3%

Based on 12 completed trials

Completion Rate
92%(12/13)
Active Trials
0(0%)
Results Posted
100%(12 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_3
9
69%
Ph phase_4
1
8%
Ph phase_2
1
8%

Phase Distribution

0

Early Stage

1

Mid Stage

10

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
1(9.1%)
Phase 3Large-scale testing
9(81.8%)
Phase 4Post-market surveillance
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.3%

12 of 13 finished

Non-Completion Rate

7.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(12)
Terminated(1)

Detailed Status

Completed12
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
92.3%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (9.1%)
Phase 39 (81.8%)
Phase 41 (9.1%)

Trials by Status

terminated18%
completed1292%

Recent Activity

0 active trials
Showing 5 of 13
completed

A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea

NCT04470817
completed

International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan

NCT02756819
completedphase_3

Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

NCT02480764
completedphase_4

Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

NCT02517866
completedphase_3

Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension

NCT02203916
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT04470817

A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea

Completed
NCT02756819

International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan

Completed
NCT02480764Phase 3

Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

Completed
NCT02517866Phase 4

Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

Completed
NCT02203916Phase 3

Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension

Completed
NCT01496430Phase 3

Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes

Terminated
NCT00760214Phase 3

Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension

Completed
NCT00847626Phase 3

Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension

Completed
NCT00591578Phase 3

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

Completed
NCT00696384Phase 3

A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

Completed
NCT00696436Phase 3

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Completed
NCT00591253Phase 3

Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension

Completed
NCT00362115Phase 2

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13